Research comparison
AOD-9604 vs Semaglutide
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
Research Status
Phase III
Approved
Half-Life
~30 minutes
~1 week (allows once-weekly dosing)
Mol. Weight
—
—
Admin Routes
subcutaneous, oral
subcutaneous, oral
Categories
Fat Loss & Metabolic
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic, Cardiovascular
Interaction
No interaction data on file
Mechanism
Pharmacokinetics
Research Findings
Safety
Related comparisons